- Clinical Trials
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.
Gallagher’s appointment demonstrates the Company’s commitment to building a world-class intellectual property portfolio
Dr. Gannon will oversee and manage regulatory matters for the Company’s upcoming clinical trials, including its lead drug candidate in combination with Tagrisso® for which Fast Track Designation was received earlier this year.
Rodney Varner, Chairman and Chief Executive Officer of Genprex, will present virtually to an online audience on September 1, 2020 at 1:20 p.m. ET.
Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes
Genprex’s CEO participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.
Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials
Genprex was added to the Russell 3000® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution.
Company executes on corporate communication strategy and advances drug branding initiatives